- Home
- ANAB vs BORR Comparison
ANAB vs BORR Comparison
Compare ANAB & BORR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- BORR
- Stock Information
- Founded
- ANAB 2005
- BORR 2016
- Country
- ANAB United States
- BORR Bermuda
- Employees
- ANAB N/A
- BORR N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- BORR Oil & Gas Production
- Sector
- ANAB Health Care
- BORR Energy
- Exchange
- ANAB Nasdaq
- BORR Nasdaq
- Market Cap
- ANAB 1.0B
- BORR 909.1M
- IPO Year
- ANAB 2017
- BORR 2019
- Fundamental
- Price
- ANAB $42.39
- BORR $3.30
- Analyst Decision
- ANAB Buy
- BORR Hold
- Analyst Count
- ANAB 12
- BORR 2
- Target Price
- ANAB $63.80
- BORR $3.75
- AVG Volume (30 Days)
- ANAB 735.4K
- BORR 4.8M
- Earning Date
- ANAB 11-04-2025
- BORR 11-05-2025
- Dividend Yield
- ANAB N/A
- BORR 0.61%
- EPS Growth
- ANAB N/A
- BORR N/A
- EPS
- ANAB N/A
- BORR 0.28
- Revenue
- ANAB $169,467,000.00
- BORR $1,024,500,000.00
- Revenue This Year
- ANAB $37.52
- BORR $0.04
- Revenue Next Year
- ANAB N/A
- BORR N/A
- P/E Ratio
- ANAB N/A
- BORR $11.68
- Revenue Growth
- ANAB 196.42
- BORR 5.83
- 52 Week Low
- ANAB $12.21
- BORR $1.55
- 52 Week High
- ANAB $43.31
- BORR $4.23
- Technical
- Relative Strength Index (RSI)
- ANAB 71.33
- BORR 57.71
- Support Level
- ANAB $33.10
- BORR $2.89
- Resistance Level
- ANAB $43.31
- BORR $3.34
- Average True Range (ATR)
- ANAB 2.88
- BORR 0.18
- MACD
- ANAB 0.51
- BORR -0.01
- Stochastic Oscillator
- ANAB 91.49
- BORR 55.24
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.